PD-L1, an important PD-1 ligand
Programmed death-ligand 1 (PD-1) serves as an important immunocheckpoint receptor that is actively studied in the context of clinical cancer immunotherapy.
PD-L1 is widely expressed and is frequently overexpressed by tumor cells thereby limiting T cell activity and blocks antitumor immune responses.
We offer peptide inhibitors (peptide ligands) that target human PD-1 (hPD-1). The peptide ligands contain sequences with key anchor residues that impact the binding of PD-L1 ligands to hPD-1.